Biohaven (BHVN) Cash & Equivalents (2021 - 2026)

Biohaven has reported Cash & Equivalents for 6 years, with the latest figure at $273.1 million in Q1 2026.

• Quarterly Cash & Equivalents rose 177.47% year-over-year to $273.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $273.1 million (up 177.47% YoY) and the FY2025 annual result came in at $230.0 million, up 131.97% from the prior year.
• Cash & Equivalents climbed to $273.1 million in Q1 2026 per BHVN's latest filing, from $230.0 million in the prior quarter.
• Over five years, Cash & Equivalents peaked at $273.1 million in Q1 2026 and troughed at $23.2 million in Q2 2022.
• A 5-year average of $147.6 million and a median of $147.6 million in 2023 frame the typical range for Cash & Equivalents.
• The sharpest annual moves came in 2022 and 2023: Cash & Equivalents sank 85.99% in 2022, then soared 536.01% in 2023.
• Over 5 years, Cash & Equivalents stood at $204.9 million in 2022, then climbed by 21.24% to $248.4 million in 2023, then tumbled by 60.09% to $99.1 million in 2024, then surged by 131.97% to $230.0 million in 2025, then advanced by 18.75% to $273.1 million in 2026.
• According to Business Quant data, Cash & Equivalents over the past three periods registered $273.1 million, $230.0 million, and $184.8 million for Q1 2026, Q4 2025, and Q3 2025 respectively.